| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/0961203307088291
Adalimumab-induced lupus erythematosusDepartment of Dermatology, Hospital Clínico Universitario, Valencia, Spain; Dermatology Unit, Hospital Quirón, Valencia, Spain, jmmart{at}eresmas.com
Dermatology Unit, Hospital Quirón, Valencia, Spain
Department of Pathology, Hospital Quirón, Valencia, Spain
Department of Pathology, Hospital Quirón, Valencia, Spain
Dermatology Unit, Hospital Quirón, Valencia, Spain Adalimumab, an anti-tumour necrosis factor agent, especially used in the treatment of rheumatoid arthritis, has a good safety profile. One of the most common side-effects of adalimumab is the development of autoantibodies. Despite the induction of autoantibodies, the clinical presentation of immune-mediated complications upon adalimumab therapy, including a lupus-like syndrome, is very rare. We have recently evaluated a new case of adalimumab-induced lupus erythematosus.
Key Words: adalimumab drug-induced lupus erythematosus leflunomide
|